Amgen Inc. (FRA:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 154.95B +10.3% |
| Revenue (ttm) | 30.66B +10.6% |
| Net Income | 5.97B +65.6% |
| EPS | 11.02 +65.1% |
| Shares Out | n/a |
| PE Ratio | 25.95 |
| Forward PE | 16.20 |
| Dividend | 8.52 (2.99%) |
| Ex-Dividend Date | Nov 21, 2025 |
| Volume | 113 |
| Average Volume | 167 |
| Open | 285.20 |
| Previous Close | 288.15 |
| Day's Range | 285.20 - 285.20 |
| 52-Week Range | 230.00 - 304.75 |
| Beta | n/a |
| RSI | 51.56 |
| Earnings Date | Feb 3, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial numbers in USD Financial StatementsNews
M3 Advisory Group, LLC Sells 198 Shares of Amgen Inc (AMGN)
M3 Advisory Group, LLC Sells 198 Shares of Amgen Inc (AMGN)
Aspire Capital Advisors LLC Sells 42 Shares of Amgen Inc (AMGN)
Aspire Capital Advisors LLC Sells 42 Shares of Amgen Inc (AMGN)
Bouchey Financial Group Ltd Sells 4 Shares of Amgen Inc (AMGN)
Bouchey Financial Group Ltd Sells 4 Shares of Amgen Inc (AMGN)
MRA Advisory Group Sells 264 Shares of Amgen Inc (AMGN)
MRA Advisory Group Sells 264 Shares of Amgen Inc (AMGN)
Birchcreek Wealth Management, LLC Sells 165 Shares of Amgen Inc (AMGN)
Birchcreek Wealth Management, LLC Sells 165 Shares of Amgen Inc (AMGN)
Hopwood Financial Services, Inc. Buys 18 Shares of Amgen Inc (AMGN)
Hopwood Financial Services, Inc. Buys 18 Shares of Amgen Inc (AMGN)
2 Dividend Stocks to Buy and Hold For 10 Years
These drugmakers can perform well despite competition and patent cliffs facing them. Both have excellent dividend programs and have increased their payouts at a good clip.
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus
FOLD, MU and AMGN delivered sharp gains as Zacks strategies beat key benchmarks despite tariff fears, policy uncertainty and volatile markets.
Amgen's Weight-Loss Drug Shows Promise With Less Frequent Dosing
Amgen reported early Phase 2 data suggesting patients kept weight off with less frequent dosing, a potential differentiator from Eli Lilly and Novo Nordisk.
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc. (NASDAQ: AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment . • ...
Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses
At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc. (NASDAQ: AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment.
Amgen CEO Bob Bradway goes one-on-one with Jim Cramer
Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.
Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss
Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.
Amgen CEO: There are a bunch of ways to win for patients when it comes to weight loss
Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.
Amgen CEO Bob Bradway goes one-on-one with Jim Cramer
Amgen CEO Bob Bradway joins 'Mad Money' host Jim Cramer to talk its rare disease business, its weight-loss drug offering, what is in Amgen's pipeline, and more.
Amgen CEO says weight loss drug can address 'patient persistence issue'
Amgen CEO Bob Bradway discussed his company's weight loss drug in an interview with CNBC's Jim Cramer.
Ro partners with Amgen to study barriers to obesity care, GLP-1 access
U.S. telehealth firm Ro said on Tuesday it has entered a research collaboration with drugmaker Amgen to examine challenges patients and providers face in accessing obesity treatments, including GLP-1 ...
Amgen (AMGN) Reveals Promising Results from MariTide Phase 2 Study
Amgen (AMGN) Reveals Promising Results from MariTide Phase 2 Study
Amgen Inc at JPMorgan Healthcare Conference Transcript
Amgen Inc at JPMorgan Healthcare Conference Transcript
Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Amgen says MariTide helped trial patients maintain weight loss
An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while a second mid-stage trial in diabetes patients showed that it lowered their blood...
Amgen to announce data on obesity drug MariTide at healthcare conference
Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on Monday to unveil results from a mid-stage trial extension designed to show if ...
Key Executive Transition from Amgen (AMGN) to BioMarin
Key Executive Transition from Amgen (AMGN) to BioMarin
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
"6 in '26" expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete a...
The 2026 Dogs Of The Dow: 10 High-Yield Blue Chips
The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite. The index's top payers dish up to 6.8%.